Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zai Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zai Lab's regulatory disclosures and financial reporting.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADSs). On May 13–14, 2026, Du Ying exercised stock options to acquire 100,000 ADSs at a price of $1.74 per ADS equivalent, then sold 100,000 ADSs in open-market transactions at weighted average prices of $19.4432, $20.2223, and $20.0915 per ADS.
After these transactions, Du Ying directly holds 1,122,626 ADSs and 361,092 stock options outstanding. All trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the timing was set in advance rather than decided opportunistically.
ZLAB reported proposed sales of American Depositary Shares by an insider, listing multiple transactions and dates. The notice itemizes repeated proposed dispositions of 50,000 ADS lots on several dates and smaller dispositions (for example, 1,067 ADS on 03/11/2026). Transaction entries show trade dates, share counts and gross proceeds for each line item.
ZLAB insider reported proposed and completed sales of American Depositary Shares (ADS). The filing lists multiple ADS dispositions by Ying Du, including 50,000-share transactions dated 03/04/2026, 03/05/2026, 03/06/2026, 03/09/2026 and 05/13/2026. Several other smaller ADS sales are shown in March and April 2026.
ZLAB insider notice of proposed resale activity: multiple American Depositary Shares were listed as sold or to be sold under restricted stock vesting and compensation arrangements. The excerpt lists specific vesting entries of 550 ADS (04/03/2025) and 2,967 ADS (08/17/2025), and several sales by an individual during March–April 2026.
Issuer reported Form 144 notice to sell 50,000 American Depositary Shares. The filing lists an option granted on 08/25/2016 and a planned sale of 50,000 ADS on 05/13/2026 for $960,000.00. The filing also reports multiple ADS dispositions by Ying Du between 03/04/2026 and 04/06/2026, including several blocks of 50,000 ADS and smaller sales that together appear in the reported transaction history.
Zai Lab Limited reported first-quarter 2026 revenue of $99.6 million, with net product revenue of $95.6 million, down 10% year over year, and a net loss of $51.0 million (loss of $0.05 per ordinary share).
Sales declined mainly because ZEJULA revenue fell 39% to $30.0 million after volume-based procurement for generic olaparib, and VYVGART revenue softened following a pricing adjustment tied to NRDL renewal. These pressures were partly offset by strong growth from XACDURO, whose revenue rose to $8.6 million, and continued gains from NUZYRA and OPTUNE.
The company increased research and development spending to $65.6 million, driven by higher clinical trial and licensing costs, while selling, general, and administrative expenses rose modestly to $65.1 million. Zai Lab ended the quarter with $761.3 million in cash, cash equivalents, current restricted cash, and short-term investments and $213.8 million in short-term debt, supporting ongoing late-stage programs and new collaborations highlighted in oncology and immunology.
Zai Lab Limited reported first-quarter 2026 total revenue of $99.6 million, down 6% year over year, as weaker oncology sales offset growth in newer products. Net product revenue was $95.6 million, a 10% decline, mainly from lower ZEJULA and VYVGART sales.
ZEJULA revenue fell to $30.0 million from $49.5 million due to volume-based procurement for a competing generic, while VYVGART slipped to $17.6 million after a pricing adjustment tied to NRDL renewal. XACDURO and NUZYRA grew to $8.6 million and $16.3 million, respectively.
Research and development expenses rose to $65.6 million and SG&A to $65.1 million, leading to a GAAP operating loss of $69.4 million and net loss of $51.0 million, or $0.05 per ordinary share. Zai Lab ended March 31, 2026 with $761.3 million in cash, equivalents, short-term investments, and current restricted cash.
The company highlighted standout intracranial response data for its DLL3-targeting ADC zocilurtatug pelitecan in small cell lung cancer and epNECs, new collaborations with Amgen and Boehringer Ingelheim, advancing atopic dermatitis candidate ZL-1503, and positive Phase 3 data from partners’ programs povetacicept in IgA nephropathy and elegrobart in thyroid eye disease.
Zai Lab Limited is calling its 2026 Annual General Meeting for June 17, 2026, in Shanghai with a concurrent virtual option. Shareholders will vote on re-electing nine directors, appointing KPMG LLP and KPMG as 2026 auditors, and giving the Board authority to set auditor fees.
They will also cast an advisory “say-on-pay” vote on named executive officer compensation. Two key capital authorizations are proposed: a general mandate allowing the Board to issue or resell up to 10% of issued ordinary shares and a separate mandate to repurchase up to 10% of issued ordinary shares, each effective until the 2027 meeting.
Zai Lab Limited is soliciting shareholder votes at its 2026 Annual General Meeting to be held on June 17, 2026, seeking re-election of nine directors, approval of KPMG LLP/KPMG as auditors for the year ending December 31, 2026, and shareholder mandates to issue and repurchase up to 10% of issued ordinary shares.
The record date for voting is April 16, 2026. The proxy materials reference 1,134,128,030 issued ordinary shares as of April 10, 2026, implying a 10% cap equal to 113,412,803 shares for each proposed mandate.